PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
1.130
-0.030 (-2.59%)
Sep 15, 2025, 10:40 AM EDT - Market open
PDS Biotechnology Employees
PDS Biotechnology had 24 employees as of December 31, 2024. The number of employees decreased by 1 or -4.00% compared to the previous year.
Employees
24
Change (1Y)
-1
Growth (1Y)
-4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,525,091
Market Cap
53.14M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 24 | -1 | -4.00% |
Dec 31, 2023 | 25 | -1 | -3.85% |
Dec 31, 2022 | 26 | 4 | 18.18% |
Dec 31, 2021 | 22 | 7 | 46.67% |
Dec 31, 2020 | 15 | 0 | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PDSB News
- 13 days ago - PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 21 days ago - PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer - GlobeNewsWire
- 4 weeks ago - PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update - GlobeNewsWire
- 5 weeks ago - PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - GlobeNewsWire
- 3 months ago - PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC - GlobeNewsWire
- 3 months ago - PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire